Perrin Biological: Abnormal fluctuations in stock trading do not involve undisclosed information that should be disclosed.

Pailin Bioscience announced that the closing price of the company's stock deviated by more than 20% for three consecutive trading days, indicating abnormal fluctuations. After verification, apart from the termination of the control transfer disclosed on June 18, there is no need to correct or supplement the company's previous information. The company's operations have been normal recently, with no significant changes in internal and external environments. There are no undisclosed significant matters or trading of the company's stock by major shareholders. The company reminds investors to pay attention to investment risks.